Chlamydia pneumoniae

The Lung and the Heart

  • Luigi Allegra
  • Francesco Blasi

Table of contents

  1. Front Matter
    Pages I-VIII
  2. History of Chlamydia pneumoniae (TWAR)

    1. J. T. Grayston, S.-P. Wang
      Pages 1-8
  3. Chlamydia pneumoniae: Culture Methods

  4. Serology for Chlamydia pneumoniae (TWAR)

  5. Chlamydia pneumoniae: Molecular Biology Methods

    1. J. Boman, C. A. Gaydos
      Pages 24-32
  6. Chlamydia pneumoniae Infections: Applications of Laboratory Methods

  7. Chlamydia pneumoniae: How to Document Respiratory Infection

  8. Chlamydia pneumoniae: Epidemiology

    1. F. Blasi, C. Arosio, R. Cosentini
      Pages 52-61
  9. Pharmacological and Pharmacokinetic Basis of Chlamydia pneumoniae Treatment

  10. Chlamydia pneumoniae: Clinical Characteristics of Acute Respiratory Infections

  11. Are Atypical Pathogens Important for Patients with Community-Acquired Pneumonia?

  12. Immunology of Chlamydia pneumoniae

    1. M. Leinonen
      Pages 88-95
  13. Chronic Chlamydia pneumoniae Infections

  14. Chlamydia pneumoniae:A New Possible Cause of Asthma

    1. D. L. Hahn, L. Allegra
      Pages 114-123
  15. Chlamydia pneumoniae: An Important Pathogen in Chronic Bronchitis

  16. Chlamydia pneumoniae: A New Threat for HIV-infected Subjects

    1. R. Cosentini, F. Blasi, L. Fagetti
      Pages 134-138
  17. Chlamydia pneumoniae: Epidemiology of a New Cardiovascular Risk Factor

    1. F. Blasi, R. Cosentini, P. Tarsia
      Pages 139-151
  18. Chlamydia pneumoniae and Atherosclerosis: Mechanisms of Vascular Damage

  19. Chlamydia pneumoniae and Atherosclerosis: Animal Models

    1. L. A. Campbell, C.-C. Kuo
      Pages 163-170
  20. Open and Controlled Intervention Trials for “Unusual” Anti-Chlamydia pneumoniae Indications: Asthma, Atherosclerosis, Myocardial Infarction

  21. Chlamydia pneumoniae Infections in Children

    1. G. L. Biscione, S. L. Johnston
      Pages 197-203
  22. Perspectives and Perceptions on the Clinical Relevance of Chlamydia pneumoniae Infection

About this book


Chlamydia pneumoniae is now recognized as an important human pathogen. Chlamydia pneumoniae is involved in 5%-15% of community acquired pneumonias, and recent data indicate its relevance in severe pneumonia and as a respiratory pathogen in immunocompromised subjects. A causal role for Chlamydia pneumoniae in the initiation, exacerbations and promotion of asthma has been suggested. Approximately 5% of chronic bronchitis exacerbations have been attributed to Chlamydia pneumoniae infections, and chronic infection may facilitate access of other pathogens to the lower respiratory tract. Another field of potential great social impact is the possible involvement of Chlamydia pneumoniae in the pathogenesis of atherosclerosis and related cardiovascular diseases. This book presents the current state-of-the-art knowledge on Chlamydia pneumoniae infection and highlights future lines of research.


Laboratory antibiotic asthma breathing cardiovascular disease epidemiology infection intervention molecular biology perception pharmacokinetics pharmacology respiratory infection treatment vascular disease

Editors and affiliations

  • Luigi Allegra
    • 1
  • Francesco Blasi
    • 1
  1. 1.Institute of Respiratory DiseasesUniversity of Milan, IRCCS Ospedale MaggioreMilanItaly

Bibliographic information